Researchers from Tel Aviv University and the Israel Institute for Biological Research have developed an mRNA-based vaccine that’s effective against a type of bacteria lethal to humans.
Their study, published in Science Advances, was conducted in animal models and demonstrated that all treated animals were fully protected against the bacteria. According to the researchers, their new technology can enable rapid development of effective vaccines for bacterial diseases, including diseases caused by antibiotic-resistant bacteria.
“So far mRNA vaccines, such as the COVID-19 vaccines familiar to all of us, were assumed to be effective against viruses but not against bacteria,” says Tel Aviv University’s Edo Kon, PhD, a lead author on the study, in a press release. “The great advantage of these vaccines, in addition to their effectiveness, is the ability to develop them very quickly. Once the genetic sequence of the virus SARS-CoV2 was published, it took only 63 days to begin the first clinical trial. However, until now scientists believed that mRNA vaccines against bacteria were biologically undoable. In our study, we proved that it is in fact possible to develop 100%-effective mRNA vaccines for deadly bacteria.”
The researchers explain that viruses depend on external cells for their reproduction. Inserting its own mRNA molecule into a human cell, a virus uses our cells as a factory for producing viral proteins based on its own genetic material, namely replicates of itself. In mRNA vaccines, this same molecule is synthesized in a lab, then wrapped in lipid nanoparticles resembling the membrane of human cells.
When the vaccine is injected into our body, the lipids stick to our cells, and consequently, the cells produce viral proteins. The immune system, becoming familiar with these proteins, learns how to protect our body in the event of exposure to the real virus.
“Since viruses produce their proteins inside our cells, the proteins translated from the viral genetic sequence are similar to those translated from the lab-synthesized mRNA. Bacteria, however, are a whole different story. They don’t need our cells to produce their own proteins. And since the evolutions of humans and bacteria are quite different from one another, proteins produced in bacteria can be different from those produced in human cells, even when based on the same genetic sequence,” says Kon in a press release.
Kon continues, “Researchers have tried to synthesize bacterial proteins in human cells, but exposure to these proteins resulted in low antibodies and a general lack of protective immune effect, in our bodies. This is because, even though the proteins produced in the bacteria are essentially identical to those synthesized in the lab, being based on the same ‘manufacturing instructions,’ those produced in human cells undergo significant changes, like the addition of sugars, when secreted from the human cell. To address this problem, we developed methods to secrete the bacterial proteins while bypassing the classical secretion pathways, which are problematic for this application.
“The result was a significant immune response, with the immune system identifying the proteins in the vaccine as immunogenic bacterial proteins. To enhance the bacterial protein’s stability and make sure that it does not disintegrate too quickly inside the body, we buttressed it with a section of human protein. By combining the two breakthrough strategies we obtained a full immune response.”
